Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies
JournalTrends in Molecular Medicine
MetadataShow full item record
AbstractSystemic lupus erythematosus (SLE) is a multisystem, chronic autoimmune disease where treatment varies by patient and disease activity. Strong preclinical results and clinical correlates have motivated development of many drugs, but many of these have failed to achieve efficacy in clinical trials. FDA approval of belimumab in 2011 was the first successful SLE drug in nearly six decades. In this article, we review insights into the molecular and clinical heterogeneity of SLE from transcriptomics studies and detail their potential impact on drug development and clinical practices. We critically examine the pipeline of SLE drugs, including past failures and their associated lessons and current promising approaches. Finally, we identify opportunities for integrating these findings and drug development with new multidisciplinary advances to enhance future SLE treatment. Copyright 2020 Elsevier Ltd
systemic lupus erythematosus
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15332
- Belimumab: review of use in systemic lupus erythematosus.
- Authors: Boyce EG, Fusco BE
- Issue date: 2012 May
- Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
- Authors: Jordan NP, D'Cruz DP
- Issue date: 2015
- Emerging B-Cell Therapies in Systemic Lupus Erythematosus.
- Authors: Bag-Ozbek A, Hui-Yuen JS
- Issue date: 2021
- A critical review of clinical trials in systemic lupus erythematosus.
- Authors: Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R
- Issue date: 2016 Sep
- Belimumab in systemic lupus erythematosus: an update for clinicians.
- Authors: Kim SS, Kirou KA, Erkan D
- Issue date: 2012 Jan